GPT and metabolic dysfunction-associated steatotic liver disease: After analyzing the biochemical and histopathological changes brought about by the drug interventions on the HFD-MASLD Sprague-Dawley rat model, we conclude that glimepiride, which exhibited AST and ALT reductions along with a four-point NAS reduction, offers itself as a promising drug candidate for human clinical trials for MASLD.